Trial Profile

A Retrospective Study Investigating the Potential Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Timing of PD1 Inhibition with Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Ramucirumab plus Docetaxel (RD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Sep 2018 Results from a cohort of patients who received ramucirumab+docetaxel as third line treatment presented at the 19th World Conference on Lung Cancer
26 Sep 2018 Results describing baseline characteristics, treatment patterns, and clinical outcomes among RDP patients subsequently treated with ram+doc in the United States presented at the 19th World Conference on Lung Cancer
26 Sep 2018 Results (n=62) presented at the 19th World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com